Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
Chemogenetic characterization through in vitro evolution combined with whole-genome analysis can identify antimalarial drug targets and drug-resistance genes. We performed a genome analysis of 262 Plasmodium falciparum parasites resistant to 37 diverse compounds. We found 159 gene amplifications and 148 nonsynonymous changes in 83 genes associated with drug-resistance acquisition, where gene amplifications contributed to one-third of resistance acquisition events. Beyond confirming previously identified multidrug-resistance mechanisms, we discovered hitherto unrecognized drug target–inhibitor pairs, including thymidy...
Source: ScienceNOW - January 11, 2018 Category: Science Authors: Cowell, A. N., Istvan, E. S., Lukens, A. K., Gomez-Lorenzo, M. G., Vanaerschot, M., Sakata-Kato, T., Flannery, E. L., Magistrado, P., Owen, E., Abraham, M., LaMonte, G., Painter, H. J., Williams, R. M., Franco, V., Linares, M., Arriaga, I., Bopp, S., Core Tags: Genetics, Microbiology r-articles Source Type: news
Cluster of resistant tuberculosis pathogen discovered
(University of Zurich) Between February and Nov. 2016, the Institute of Medical Microbiology at the University of Zurich discovered a multidrug-resistant Mycobacterium tuberculosis in eight refugees arriving in Europe from the Horn of Africa. The analyses provided an impulse for launching a transnational investigation and developing a pan-European alerting system. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 9, 2018 Category: Biology Source Type: news
Research paves the way for treatment strategies of multidrug-resistant chronic infections
(Technical University of Denmark) A new study published in Cell Press finds that antibiotic treatment of chronic infections can be optimized by targeting vulnerabilities of antibiotic-resistant pathogens paving the way for more effective treatment strategies. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 5, 2018 Category: Infectious Diseases Source Type: news
Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - January 2, 2018 Category: Drugs & Pharmacology Source Type: news
Bedaquiline and Delamanid Treatment in Drug-Resistant TB Bedaquiline and Delamanid Treatment in Drug-Resistant TB
Combination therapy with bedaquiline and delamanid may be another option for patients with multidrug-resistant tuberculosis and limited treatment options.Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news
